This purified recombinant monoclonal antibody is a human anti-IL23α that selectively binds to the p19 subunit of heterodimeric IL-23, which is composed of p19 and IL-12 p40. The variable regions for this antibody are based on an FDA-approved drug Skyrizi® (risankizumab-rzaa), sold by AbbVie. This antibody has been tested for specific binding affinity to IL23α/IL12β antigen.